Author, as appears in the article.: Teira, Ramon; Diaz-Cuervo, Helena; Aragao, Filipa; Munoz, Josefa; Galindo, Pepa; Merino, MariaDolores; de la Fuente, Belen; Sepulveda, Maria Antonia; Domingo, Pere; Garcia, Josefina; Castano, Manuel; Ribera, Esteve; Geijo, Paloma; Romero, Alberto; Peraire, Joaquim; Deig, Elisabeth; Roca, Bernardino; Martinez, Elisa; Estrada, Vicente; Montero, Marta; Berenguer, Juan; Espinosa, Nuria;
Department: Medicina i Cirurgia
URV's Author/s: Peraire Forner, José Joaquin
Keywords: Tenofovir disoproxil fumarate Tenofovir alafenamide Switch Risk Retrospective Resolution Renal-function Regimen Pharmacokinetics Hiv Exposure Estimated glomerular filtration rate Emtricitabine Alafenamide
Abstract: Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Methods: Data were from a multicenter Spanish PLWH cohort. Patients with a baseline estimated glomerular filtration rate (eGFR-EPI) measurement, >= 1 follow-up measurement, >= 30 days treatment with F/TAF, and who switched from F/TDF to F/TAF with no change in third agent were included. Multivariate mixed linear models were used to evaluate change from baseline over time in eGFR-EPI. eGFR-EPI changes before and after switch were analyzed in a matched patient subgroup. Results: Overall, 340 patients were included. Mean (95% CI) eGFR-EPI in patients with baseline eGFR-EPI <90 ml/min/1.73m(2) (n = 125) was 79.6 (78.0; 81.2) ml/min/1.73m(2) at baseline and 81.3 (79.9; 82.7) ml/min/1.73m(2) at 12 months after switch. In the patient-matched subgroup (n = 175), median annual eGFR-EPI declined -4.24 ml/min/1.73m(2) while on F/TDF and increased +0.93 ml/min/1.73m(2) after switch to F/TAF (P < 0.0001). In patients with baseline eGFR-EPI <90 ml/min/1.73m(2), median annual eGFR-EPI increased +4.19 mL/min/1.73m(2) after switch (P < 0.0001). Conclusion: Switching from F/TDF to F/TAF-based TT regimens while maintaining the same third agent numerically improved eGFR-EPI in PLWH with baseline eGFR-EPI <90 mL/min/1.73m(2). eGFR-EPI improved significantly when comparing progression while on F/TDF vs progression after switch, confirming beneficial renal effects of switching to F/TAF in a clinical practice setting.
Thematic Areas: Pharmacology (medical) Pharmacology & pharmacy Infectious diseases
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: joaquim.peraire@urv.cat
Author identifier: 0000-0001-7808-5479
Record's date: 2024-07-27
Papper version: info:eu-repo/semantics/publishedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Hiv Research And Clinical Practice. 22 (3): 78-85
APA: Teira, Ramon; Diaz-Cuervo, Helena; Aragao, Filipa; Munoz, Josefa; Galindo, Pepa; Merino, MariaDolores; de la Fuente, Belen; Sepulveda, Maria Antonia; (2021). eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. Hiv Research And Clinical Practice, 22(3), 78-85. DOI: 10.1080/25787489.2021.1955197
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV